Veterinary Autoimmune Disease Therapeutics Market Report 2026

The veterinary autoimmune disease therapeutics market size has grown strongly in recent years. It will grow from $3.46 billion in 2025 to $3.69 billion in 2026 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to limited treatment options for animal autoimmune diseases, high prevalence of hypothyroidism and pemphigus, reliance on corticosteroids as primary therapy, growing pet ownership, increasing veterinary consultations.

The veterinary autoimmune disease therapeutics market size is expected to see strong growth in the next few years. It will grow to $4.61 billion in 2030 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to advancements in immunomodulatory therapies, development of novel oral and injectable formulations, rising awareness of autoimmune conditions in companion animals, expansion of veterinary hospital and clinic networks, increasing adoption of precision medicine approaches. Major trends in the forecast period include rising use of corticosteroids and immunosuppressive therapies, increasing focus on companion animal autoimmune disease management, expansion of veterinary hospital and clinic networks, development of oral and injectable formulations for enhanced compliance, growing awareness of rare autoimmune diseases in animals.

The rising funding for research in veterinary medicine is expected to drive the growth of the veterinary autoimmune disease therapeutics market in the coming years. Veterinary medicine focuses on the prevention, diagnosis, and treatment of diseases, disorders, and injuries in animals. Increased research funding is being driven by factors such as the rise of zoonotic diseases, expansion of the pet industry, advances in animal health technologies, agricultural demands, and wildlife conservation initiatives. This funding supports studies on disease mechanisms, the development of diagnostic tools, and new treatment options, thereby enhancing the ability of veterinary medicine to effectively diagnose and manage autoimmune conditions. For example, in September 2025, according to the American Veterinary Medical Association (AVMA), a US-based non-profit association, the USDA Veterinary Service Grant Program allocated $3.8 million in 2024, with plans to increase funding up to $15 million in subsequent years. Therefore, increased research funding in veterinary medicine is supporting growth in the veterinary autoimmune disease therapeutics market.

Major companies in the veterinary autoimmune disease therapeutics market are focusing on developing advanced technological solutions, such as RenBiologics, to meet key industry needs. RenBiologics specializes in creating innovative therapies for kidney-related conditions and chronic diseases, with a focus on biologics and regenerative medicine to improve outcomes in areas like renal function and transplant success. For example, in January 2024, Biocytogen, a China-based biotechnology company, launched a new sub-brand, RenBiologics, to focus on the out-licensing of fully human antibodies for therapeutic development. This initiative aims to leverage Biocytogen's extensive library of over 400,000 fully human antibody sequences, created using its proprietary RenMice platform. RenBiologics will support collaborations with pharmaceutical and biotechnology companies for co-development and licensing of these antibodies, advancing the potential for novel antibody-based therapeutics. The launch underscores Biocytogen's commitment to becoming a global leader in antibody discovery and accelerating the development of innovative treatments across multiple therapeutic areas.

In March 2024, AbbVie Inc., a US-based biopharmaceutical company specializing in medicines and solutions for complex health issues, acquired Landos Biopharma for $137.5 million. This acquisition enables AbbVie to expand its portfolio in inflammatory bowel diseases by advancing innovative therapies such as NX-13, addressing significant unmet needs in patient care. Landos Biopharma, also based in the US, focuses on developing autoimmune therapies, with potential applications for treating similar conditions in animals.

Major companies operating in the veterinary autoimmune disease therapeutics market are Pfizer Inc, Merck & Co Inc, AbbVie Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline, Takeda Pharmaceutical Company, Amgen Inc., Teva Pharmaceuticals Industries Ltd., Zoetis Inc, Boehringer Ingelheim International GmbH, Sumitomo Pharma Co. Ltd., IDEXX Laboratories Inc., Cipla Inc., Mallinckrodt Pharmaceuticals, Virbac S.A, Dechra Pharmaceuticals plc, Neogen Corporation, Vetoquinol S.A., Norbrook Laboratories Limited, Heska Corporation, Bimeda Holdings PLC, Bayer Animal Health Inc, Aratana Therapeutics Inc, Hester Biosciences Limited.

North America was the largest region in the veterinary autoimmune disease therapeutics market in 2025. The regions covered in the veterinary autoimmune disease therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the veterinary autoimmune disease therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the veterinary autoimmune disease therapeutics market by raising costs of imported active pharmaceutical ingredients and biologics, impacting corticosteroids, cyclosporine, and mycophenolate formulations. Regions like north america and europe, which rely on imports for specialized drugs, face higher production costs. The tariffs have prompted manufacturers to explore local sourcing, invest in domestic production, and optimize supply chains. Positive impacts include growth opportunities for local pharmaceutical production and increased focus on cost-effective therapeutic alternatives.

The veterinary autoimmune disease therapeutics market research report is one of a series of new reports that provides veterinary autoimmune disease therapeutics market statistics, including veterinary autoimmune disease therapeutics industry global market size, regional shares, competitors with a veterinary autoimmune disease therapeutics market share, detailed veterinary autoimmune disease therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the veterinary autoimmune disease therapeutics industry. This veterinary autoimmune disease therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Veterinary autoimmune disease therapeutics encompass treatments tailored to manage and alleviate animal autoimmune conditions. These therapies are geared towards modulating or suppressing the immune response to mitigate inflammation, halt further tissue damage, and enhance the overall well-being and quality of life of affected animals. Given the complexity of these conditions, veterinary autoimmune disease therapeutics necessitate a customized approach, taking into account the specific disease, its severity, and the individual needs of the animal.

The primary types of therapy within veterinary autoimmune disease therapeutics include corticosteroids, azathioprine, cyclosporine, mycophenolate, leflunomide, cyclophosphamide, levothyroxine, folic acid, hydroxychloroquine, and chloroquine. Corticosteroids, derived from steroid hormones produced in the adrenal cortex, are commonly utilized in medicine to diminish inflammation and suppress immune activity. They are administered to various animals, including companion and livestock animals, to address conditions such as disease-type hypothyroidism, pemphigus disease, canine lupus, autoimmune hemolytic anemia, bullous pemphigoid, discoid lupus erythematosus (DLE), immune-related arthritis, among others. These therapeutic agents are typically dispensed through veterinary hospitals and clinics.

The veterinary autoimmune disease therapeutics market consists of revenues earned by entities by providing immunosuppressive medications, biologic therapies, supportive therapies and complementary therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The veterinary autoimmune disease therapeutics market also includes sales of prednisone, mycophenolate mofetil, and methotrexate. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.